PANORAMA1: Panobinostat + Bortezomib + Dexamethasone vs Placebo + Bortezomib + Dexamethasone in Relapsed Multiple Myelom
🧬 N/A
🏥 Multiple myeloma
💰 N/A
⏱ N/A
✅ 0.00
✨ 0.00
Randomized, double-blind, placebo-controlled phase 3 trial with 21-day treatment cycles. Panobinostat 20mg orally on day...
Expected: Improved progression-free survival with panobinostat combination based on preclinical synergistic an...
Brain Connectivity-Targeted tACS Trial in Early AD
🧬 MCI
🏥 Alzheimer's Disease
🔗 5 hyp
💰 $520,000
⏱ 18mo
✅ 0.50
✨ 0.50
## PROTOCOL
Expected: ## EXPECTED OUTCOMES
TRIM21-mediated K63-linked ubiquitination of G3BP1
🧬 G3BP1
🏥 N/A
🔗 4 hyp
💰 N/A
⏱ N/A
✅ 0.00
✨ 0.00
Materials: Recombinant TRIM21 E3 ligase, purified G3BP1 protein, E1/E2 enzymes (UBE1, UbcH5c), K63-only ubiquitin chains...
Expected: Quantitative predictions: (1) TRIM21 co-IPs with G3BP1 (>5-fold enrichment over IgG control, p<0.01)...
SPP1-mediated microglial synaptic engulfment assay
🧬 SPP1
🏥 Alzheimer's disease
🔗 5 hyp
💰 N/A
⏱ N/A
✅ 0.00
✨ 0.00
**Phase 1: Primary Cell Culture and SPP1 Manipulation** — Week 1-2
Expected: 1. Primary: SPP1 knockdown will reduce microglial synaptic engulfment by >40% compared to scrambled ...
Sevoflurane-induced neurotoxicity (SIN) rat model
🧬 C1qa
🏥 perioperative neurocognitive disorders
🔗 5 hyp
💰 N/A
⏱ N/A
✅ 0.00
✨ 0.00
**Phase 1: Animal Preparation and Anesthesia Protocol** — Week 1
Expected: 1. Primary: Prolonged sevoflurane will increase MWM escape latency by >50% and reduce probe trial ti...
cGAS/STING pathway activation by TDP-43-released mtDNA
🧬 CGAS
🏥 amyotrophic lateral sclerosis
🔗 1 hyp
💰 N/A
⏱ N/A
✅ 0.00
✨ 0.00
**Phase 1: iPSC-derived Motor Neuron Culture and TDP-43 Manipulation** — Week 1-3
Expected: 1. Primary: cGAS/STING inhibition will reduce TDP-43-induced NF-κB activation by >60% (p < 0.01, Coh...
Bmal1 knockout in mPFC excitatory neurons
🧬 BMAL1,HOMER1A,CAMK2A
🏥 depression
🔗 2 hyp
💰 N/A
⏱ N/A
✅ 0.00
✨ 0.00
### PHASE 1: Pre-Surgical Preparation & Baseline Assessment (Weeks 1–2)
Expected: **Conditional Bmal1 knockout efficiency**: Cre-mediated excision will reduce Bmal1 mRNA by **78–85%*...
GWAS meta-analysis of major depressive disorder across three cohorts
🧬 N/A
🏥 major depressive disorder
💰 N/A
⏱ N/A
✅ 0.00
✨ 0.00
**Phase 1: Cohort Preparation and Quality Control** — Month 1-2
Expected: 1. Primary: Identify 15-25 genome-wide significant loci (p < 5×10^-8) associated with MDD risk with ...
QTJD effects on macrophage polarization and inflammatory response
🧬 CD86, CXCL10, CD206, ARG1, MRC1
🏥 Mycoplasma pneumoniae pneumonia
🔗 3 hyp
💰 N/A
⏱ N/A
✅ 0.00
✨ 0.00
### PHASE 1: Macrophage Isolation and Culture (Day 0-2)
Expected: **CD86 mRNA expression**: QTJD treatment will increase CD86 transcript levels by 2.8 ± 0.4-fold at 5...
Human Reference Interactome (HuRI) mapping
🧬 N/A
🏥 Mendelian diseases
💰 N/A
⏱ N/A
✅ 0.00
✨ 0.00
**Phase 1: Human Protein Library Construction and Validation** — Month 1-3
Expected: 1. Primary: Generate >50,000 high-confidence binary protein-protein interactions representing 4-fold...
Double depletion rescue experiment: tau and MAP6 co-depletion
🧬 Mapt, MAP6
🏥 N/A
🔗 5 hyp
💰 N/A
⏱ N/A
✅ 0.00
✨ 0.00
**Phase 1: Primary Neuronal Culture Preparation and Transfection** — Days 1-7
Expected: 1. Primary: Complete morphological rescue in tau+MAP6 co-depleted neurons, with dendritic complexity...
MSC to chondrocyte mitochondrial transfer quantification
🧬 N/A
🏥 osteoarthritis
💰 N/A
⏱ N/A
✅ 0.00
✨ 0.00
### Phase 1: Cell Culture & Preparation (Day 0)
Expected: **Baseline transfer rate at 24h**: 12-18% of chondrocytes will display double-positive mitochondrial...
Simvastatin effects on portal hypertension in cirrhotic patients
🧬 N/A
🏥 cirrhotic portal hypertension
💰 N/A
⏱ N/A
✅ 0.00
✨ 0.00
**Study Title:** Randomized, Double-Blind, Placebo-Controlled Phase II/III Clinical Trial of Simvastatin for Reduction o...
Expected: **Primary Endpoint:** 22-28% of simvastatin-treated patients will achieve ≥20% HVPG reduction or HVP...
Cx43 and GJA1-20k overexpression effects on mitochondrial transfer
🧬 GJA1
🏥 osteoarthritis
🔗 3 hyp
💰 N/A
⏱ N/A
✅ 0.00
✨ 0.00
### Phase 1: Cell Culture & Baseline Characterization (Days 1-7)
Expected: Cx43-overexpressing MSCs will show a **2.5-3.5× increase** in mitochondrial transfer to chondrocytes...
Clinical characterization of GABRA1/GABRG2 microdeletion patient
🧬 GABRA1, GABRG2
🏥 epilepsy with optic atrophy
🔗 1 hyp
💰 N/A
⏱ N/A
✅ 0.00
✨ 0.00
### Phase 1: Initial Clinical Assessment (Day 0)
Expected: **aCGH reveals exact breakpoints:** Microdeletion spans 142-158kb on chromosome 5q34, encompassing G...
Phase I trial of NP137 in advanced endometrial cancer
🧬 NTN1
🏥 advanced endometrial carcinoma
🔗 1 hyp
💰 N/A
⏱ N/A
✅ 0.00
✨ 0.00
### Phase I Trial of NP137 in Advanced Endometrial Cancer
Expected: **DLT Rate:** ≤1/6 patients (16.7%) will experience a dose-limiting toxicity at Dose Level 1 (8 mg/k...
FK866 efficacy in IBD patient-derived lamina propria cells
🧬 NAMPT
🏥 Inflammatory bowel disease
🔗 1 hyp
💰 N/A
⏱ N/A
✅ 0.00
✨ 0.00
### PHASE 1: Patient Recruitment and Tissue Acquisition (Day -14 to Day 0)
Expected: **FK866 will suppress TNF-α release with IC₅₀ between 1-10 nM.** In IBD patient LPMNCs stimulated wi...
IDH1 and IDH2 mutation sequencing in CNS and non-CNS tumors
🧬 IDH1, IDH2
🏥 gliomas (astrocytomas, oligodendrogliomas, glioblastomas)
🔗 1 hyp
💰 N/A
⏱ N/A
✅ 0.00
✨ 0.00
**IDH1 and IDH2 Mutation Sequencing in CNS and Non-CNS Tumors**
Expected: **CNS tumor cohort**: IDH1/IDH2 mutation frequency of 75-85% in astrocytomas (WHO II-IV) and oligode...
Chi3l1 deletion in APP/PS1 mouse model of Alzheimer's disease
🧬 Chi3l1
🏥 Alzheimer's disease
🔗 5 hyp
💰 N/A
⏱ N/A
✅ 0.00
✨ 0.00
### Study Design
Expected: **Amyloid plaque burden (Thioflavin-S)** in APP/PS1;Chi3l1^-/- will be 35–45% lower than APP/PS1;Chi...
Wellspent App RCT for Problematic Social Media Use
🧬 N/A
🏥 problematic social media use
💰 N/A
⏱ N/A
✅ 0.00
✨ 0.00
Randomized controlled trial with 1:1 allocation to intervention vs control groups. Intervention group received Wellspent...
Expected: Reduction in problematic social media use, increased self-efficacy, and decreased daily screen time ...
ACEs and Motoric Cognitive Risk Syndrome in Chinese Older Adults
🧬 N/A
🏥 motoric cognitive risk syndrome
💰 N/A
⏱ N/A
✅ 0.00
✨ 0.00
Cross-sectional analysis using CHARLS data. Assessment of 12 ACE indicators across categories. MCR diagnosis based on co...
Expected: Higher prevalence of MCR in individuals with more ACEs, with depression and chronic pain serving as ...
Plant-based dietary patterns and Alzheimer's disease risk in multiethnic cohort
🧬 N/A
🏥 Alzheimer's disease and related dementias
💰 N/A
⏱ N/A
✅ 0.00
✨ 0.00
Prospective longitudinal cohort study using food frequency questionnaires at baseline (1993-1996) and 10-year follow-up ...
Expected: Higher quality plant-based diets (higher PDI and hPDI) were expected to be associated with lower ADR...
Mobile App-Based Intervention for BPSD in Community-Dwelling Dementia Patients
🧬 N/A
🏥 dementia with behavioral and psychological symptoms
💰 N/A
⏱ N/A
✅ 0.00
✨ 0.00
Single-blinded randomized controlled trial with 36 dyads randomized to intervention (mobile app for 4 weeks) or control ...
Expected: Reduction in BPSD symptoms, agitated behavior, and depression in the intervention group compared to ...
Anti-ASC antibody intracerebroventricular injection in APP/PS1 mice
🧬 ASC
🏥 Alzheimer's disease
🔗 5 hyp
💰 N/A
⏱ N/A
✅ 0.00
✨ 0.00
Intracerebroventricular administration of anti-ASC N-terminal or C-terminal antibodies to APP/PS1 mice, followed by cogn...
Expected: Improved cognitive function and reduced AD pathology following ASC antibody treatment
Preinjury ACE-I/ARB exposure and outcomes in transfused trauma patients
🧬 N/A
🏥 trauma
💰 N/A
⏱ N/A
✅ 0.00
✨ 0.00
Retrospective analysis comparing trauma patients receiving blood transfusions who had preinjury ACE-I/ARB exposure versu...
Expected: Based on previous sepsis research showing improved mortality with ACE-I/ARB use, researchers expecte...
Intensive Medical Treatment vs Usual Care in Women with ANOCA/INOCA
🧬 N/A
🏥 angina with no obstructive coronary artery disease (ANOCA/INOCA)
💰 N/A
⏱ N/A
✅ 0.00
✨ 0.00
Randomized controlled trial with participants assigned to intensive medical treatment (high-intensity statin + ACE inhib...
Expected: Reduction in major adverse cardiovascular events with intensive medical treatment compared to usual ...
rTMS for preventing chronic postsurgical pain in thoracoscopic surgery
🧬 N/A
🏥 chronic postsurgical pain
💰 N/A
⏱ N/A
✅ 0.00
✨ 0.00
Randomized controlled trial with 286 patients screened, 230 randomized to active or sham rTMS targeting left DLPFC (10 H...
Expected: Reduction in CPSP incidence, improved anxiety and depression scores, decreased inflammatory biomarke...
Real-world safety study of Lecanemab in Japanese AD patients
🧬 N/A
🏥 Alzheimer's disease
🔗 5 hyp
💰 N/A
⏱ N/A
✅ 0.00
✨ 0.00
Real-world observational study with Lecanemab treatment, brain MRI monitoring before fifth infusion, safety assessments ...
Expected: Lower incidence of adverse events in Japanese population compared to global cohorts based on previou...
Myricanol treatment in HFD-induced hyperlipidemic C57BL/6J mice
🧬 ACSL1, SCD1, PPARγ
🏥 hyperlipidemia
💰 N/A
⏱ N/A
✅ 0.00
✨ 0.00
8-week HFD induction followed by 25-day treatment with myricanol (100 or 150 mg/kg) or rosiglitazone (0.78 mg/kg). Multi...
Expected: Reduction in serum lipid levels, decreased hepatic lipid accumulation, weight loss, and modulation o...
PS-NMP shape-dependent colonic barrier damage in mice
🧬 N/A
🏥 intestinal barrier dysfunction
💰 N/A
⏱ N/A
✅ 0.00
✨ 0.00
120 five-week-old male C57BL/6J mice divided into seven groups and orally exposed to different doses of PS-NMPs (beads a...
Expected: Different shaped PS-NMPs would cause varying degrees of intestinal barrier damage with distinct mole...